Application of lytic enzyme LySMP in removing S.mitis and preventing and treating chronic obstructive pulmonary disease
By using the lyase LySMP as a drug to clear S. mitis from the lungs and lower respiratory tract, the problem of the difficulty in effectively clearing this bacterium in existing technologies has been solved, achieving the prevention and treatment of early COPD.
CN120860190BActive Publication Date: 2026-06-23SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
- Filing Date
- 2025-09-11
- Publication Date
- 2026-06-23
Smart Images
Figure CN120860190B_ABST
Abstract
The application discloses a medicine / disinfectant for removing S.mitis, which comprises a lytic enzyme LySMP. Compared with other lytic enzymes, the lytic enzyme LySMP has a unique inhibiting and killing effect on S.mitis and does not affect other bacterial flora. Since the lytic enzyme LySMP has a specific removal effect on the biomarker S.mitis of chronic obstructive pulmonary disease, the application further discloses an application of the lytic enzyme LySMP in preparation of a medicine for preventing or treating chronic obstructive pulmonary disease.
Need to check novelty before this filing date? Find Prior Art